GlassScriptPhysician profile
Gabriel Pettersen
NPI 1740251727
$3,271.24
in general payments reported to CMS, 2019-2025
28 companies · $604 in 2025
The $604 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.57 · 2020: $64.52 · 2021: $752 · 2022: $709 · 2023: $738 · 2024: $373 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $344.54 | 2020-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $281.12 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $246.77 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $243.16 | 2023-2025 | Zepbound, Mounjaro |
| Braintree Laboratories, INC. | $235.12 | 2021-2025 | Sutab, Suflave |
| Amgen INC. | $233.51 | 2023-2025 | Repatha, Otezla, Otezla |
| Idorsia Pharmaceuticals US INC | $198.53 | 2022-2024 | Quviviq |
| Pfizer INC. | $187.85 | 2020-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $169.55 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $164.17 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.79 | 2019-2022 | |
| Exact Sciences Corporation | $121.00 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astellas Pharma US INC | $96.81 | 2023-2024 | Veozah |
| Antares Pharma, INC. | $81.47 | 2021-2025 | Xyosted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.04 | 2023-2024 | Xifaxan |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $76.62 | 2024-2025 | |
| Abbvie INC. | $66.95 | 2022-2023 | |
| Mylan Specialty L.P. | $54.67 | 2021 | |
| Janssen Pharmaceuticals, INC | $53.30 | 2021-2022 | |
| Amarin Pharma, INC. | $33.18 | 2021 | |
| Merck Sharp & Dohme LLC | $31.66 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.99 | 2022 | |
| Electromed, INC. | $18.52 | 2024 | Smartvest |
| Corcept Therapeutics | $17.42 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $16.57 | 2022 | |
| Organon LLC | $15.69 | 2022 | |
| Sunovion Pharmaceuticals INC. | $15.16 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Pettersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.